In 2023, the value of antiarrhythmic medicine sales in Australia stood at $20.3 million USD PPP. In 2024, sales are forecasted to reach $20.9 million, representing a year-on-year increase of approximately 3%. The upward trend continues with projected values of $21.6 million in 2025, $22.2 million in 2026, $22.7 million in 2027, and $23.1 million in 2028. This steady growth indicates a consistent annual compound growth rate (CAGR) of around 2.6% over the period from 2024 to 2028.

Future trends to watch for include:

Advances in medical technology which could lead to new, more effective treatments.
Changes in healthcare policies and reimbursement scenarios affecting medication accessibility.
Shifts in demographic factors, such as an aging population, which may drive higher demand.